Group One Trading’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.33K Hold
100
﹤0.01% 6468
2025
Q4
$7.78K Sell
100
-8,900
-99% -$601K ﹤0.01% 6952
2025
Q3
$509K Sell
9,000
-14,200
-61% -$640K ﹤0.01% 3687
2025
Q2
$1.01M Sell
23,200
-12,100
-34% -$417K ﹤0.01% 2751
2025
Q1
$966K Buy
35,300
+13,700
+63% +$499K ﹤0.01% 2491
2024
Q4
$869K Buy
21,600
+16,000
+286% +$723K ﹤0.01% 2701
2024
Q3
$265K Hold
5,600
﹤0.01% 3371
2024
Q2
$167K Sell
5,600
-13,800
-71% -$478K ﹤0.01% 3550
2024
Q1
$780K Buy
19,400
+1,500
+8% +$53.7K ﹤0.01% 2310
2023
Q4
$456K Buy
17,900
+8,500
+90% +$152K ﹤0.01% 3155
2023
Q3
$131K Sell
9,400
-100
-1% -$2.01K ﹤0.01% 4208
2023
Q2
$218K Sell
9,500
-55,400
-85% -$1.59M ﹤0.01% 3835
2023
Q1
$1.92M Sell
64,900
-79,600
-55% -$2.57M 0.01% 1560
2022
Q4
$3.61M Buy
144,500
+139,200
+2,626% +$3.71M 0.01% 1370
2022
Q3
$115K Buy
5,300
+5,200
+5,200% +$137K ﹤0.01% 4653
2022
Q2
$2K Sell
100
-1,300
-93% -$30.4K ﹤0.01% 7413
2022
Q1
$59K Buy
+1,400
New +$59.1K ﹤0.01% 5971
2021
Q4
Sell
-24,000
Closed -$1.41M 8541
2021
Q3
$1.41M Buy
+24,000
New +$1.39M ﹤0.01% 3025

Other funds holding KYMR

Group One Trading's KYMR Position: Q4 2022 in Review

Group One Trading sold out of Kymera Therapeutics (KYMR) in Q4 2022, closing a stake of 6,770 shares — an estimated $181K sold.

Group One Trading first reported a position in KYMR in Q1 2022 and held it in 2 quarters. The position peaked at $147K in Q3 2022. 121 funds tracked by Wall St. Rank hold KYMR as of Q4 2022.

  • Group One Trading reported no remaining Kymera Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Group One Trading sold 6,770 Kymera Therapeutics shares in Q4 2022, an estimated $181K.
  • Group One Trading first reported a position in Kymera Therapeutics in Q1 2022 and held it in 2 quarters.
  • Group One Trading's Kymera Therapeutics position peaked at $147K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2022.

Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.